Thermo Fisher Scientific Inc. (BMV:TMO)
Mexico · Delayed Price · Currency is MXN | Market Cap | 4.16T +27.0% |
| Revenue (ttm) | 808.43B +7.2% |
| Net Income | 121.55B +5.8% |
| EPS | 324.22 +7.4% |
| Shares Out | n/a |
| PE Ratio | 34.21 |
| Forward PE | 24.66 |
| Dividend | 32.27 (0.29%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 30 |
| Open | 11,300 |
| Previous Close | n/a |
| Day's Range | 11,300 - 11,320 |
| 52-Week Range | 7,599 - 11,320 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analy... [Read more]
Financial Performance
In 2025, Thermo Fisher Scientific's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial numbers in USD Financial StatementsNews
Thermo Fisher Scientific Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Organic growth and EPS exceeded expectations, with strong momentum in pharma, biotech, and industrial markets. AI and reshoring trends are fueling multi-year growth, while strategic M&A and capacity expansions support long-term targets of 7% organic growth by 2028.
Thermo Fisher upgraded to Buy from Neutral at UBS
UBS upgraded Thermo Fisher (TMO) to Buy from Neutral with a price target of $730, up from $540, after assuming coverage of the name. Thermo Fisher is positioned for a…
Thermo Fisher upgraded to Buy from Neutral at UBS
UBS upgraded Thermo Fisher (TMO) to Buy from Neutral with a price target of $730, up from $540.
Thermo Fisher initiated with an Outperform at CLSA
CLSA analyst Michael Luo initiated coverage of Thermo Fisher (TMO) with an Outperform rating and $748 price target
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification,...
Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at th...
Thermo Fisher introduces Thermo Scientific EMPAD G2 detector
Thermo Fisher (TMO) Scientific introduced the Thermo Scientific EMPAD G2 detector, a new detector designed to help researchers see and understand materials in detail. EMPAD G2 enables high-speed four-...
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researc...
Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass S...
Thermo Fisher complete sale of its microbiology business to Astorg for $1.075B
Thermo Fisher (TMO) Scientific announced that it has completed the sale of its microbiology business to Astorg for consideration of approximately $1.075B, consisting of cash and a $50M seller note.
Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist
LUXEMBOURG & NEW YORK & PARIS--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business fro...
Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, ...
Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost
Thermo Fisher Scientific is eyeing a 15%-20% increase in its customer base in India over the next five years, betting on the growing biopharma research and manufacturing ecosystem, the head of its I...
Thermo Fisher price target raised to $650 from $600 at Stifel
Stifel raised the firm’s price target on Thermo Fisher (TMO) to $650 from $600 and keeps a Buy rating on the shares.
Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities ...
Thermo Fisher price target raised to $600 from $510 at Piper Sandler
Piper Sandler raised the firm’s price target on Thermo Fisher (TMO) to $600 from $510 and keeps a Neutral rating on the shares. The firm is raising its price target…
Thermo Fisher price target raised to $650 from $620 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Thermo Fisher (TMO) to $650 from $620 and keeps an Overweight rating on the shares following Q2 results. The firm cited improved…
Thermo Fisher price target raised to $580 from $490 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Thermo Fisher (TMO) to $580 from $490 and keeps a Sector Perform rating on the shares after its Q2…
Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbio...
Thermo Fisher price target raised to $650 from $625 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher (TMO) to $650 from $625 and keeps an Overweight rating on the shares following the Q2 report. The…
Thermo Fisher price target raised to $650 from $630 at BofA
BofA raised the firm’s price target on Thermo Fisher (TMO) to $650 from $630 and keeps a Buy rating on the shares after “a strong quarter with very broad-based results.”…
Thermo Fisher raises FY26 EPS to $24.93-$25.33, consensus $24.85
From a previous range of $24.64-$25.12. Raises FY26 revenue to $47.4-$48.1B from a prior range of $47.30B-$48.10B.